Literature DB >> 7521944

Abnormally phosphorylated tau protein related to the formation of neurofibrillary tangles and neuropil threads in the cerebral cortex of sheep and goat.

H Braak1, E Braak, M Strothjohann.   

Abstract

Frontal sections including temporal isocortex, entorhinal region and hippocampus from aged domestic animals (dog, cat, horse, sheep and goat) were studied for Alzheimer-related changes using immunostaining with the AT8 antibody for abnormally phosphorylated tau protein and selective silver techniques for A4 amyloid and neurofibrillary changes of the Alzheimer type. The material available to us did not show A4 amyloid deposits or argyrophilic neurofibrillary changes. Only the brains of aged sheep and goat exhibited the presence of AT8-immunoreactive pyramidal cells in the entorhinal region and hippocampal formation. Two groups of AT8-positive neurons could be observed: The first group contained evenly distributed immunoreactive material in all parts of the soma, the dendrites and the axon. The neuronal processes appeared quite normal. The second group, however, showed conspicuous changes in the cellular processes consisting of a loss of immunoreactivity within the axon and the proximal dendrites and the appearance of intensely stained swellings within the curved distal dendrites. These changes were closely reminiscent to alterations of the cytoskeleton known to occur at the same location in the aging human brain and in Alzheimer's disease. The findings justify a closer look at sheep and goat when searching for suitable animal models for experimental studies of the conditions responsible for the development of Alzheimer-related neurofibrillary changes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7521944     DOI: 10.1016/0304-3940(94)90589-4

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  37 in total

1.  Fibrillar amyloid-beta-activated human astroglia kill primary human neurons via neutral sphingomyelinase: implications for Alzheimer's disease.

Authors:  Arundhati Jana; Kalipada Pahan
Journal:  J Neurosci       Date:  2010-09-22       Impact factor: 6.167

Review 2.  Animal models in the drug discovery pipeline for Alzheimer's disease.

Authors:  Debby Van Dam; Peter Paul De Deyn
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

3.  Mass Spectrometry Analysis of Lysine Posttranslational Modifications of Tau Protein from Alzheimer's Disease Brain.

Authors:  Stefani N Thomas; Austin J Yang
Journal:  Methods Mol Biol       Date:  2017

4.  Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway.

Authors:  Yuekui Li; Ling Liu; Steven W Barger; W Sue T Griffin
Journal:  J Neurosci       Date:  2003-03-01       Impact factor: 6.167

Review 5.  Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: the case for isradipine.

Authors:  Thimmappa S Anekonda; Joseph F Quinn
Journal:  Biochim Biophys Acta       Date:  2011-09-08

6.  Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation.

Authors:  J G Sheng; R A Jones; X Q Zhou; J M McGinness; L J Van Eldik; R E Mrak; W S Griffin
Journal:  Neurochem Int       Date:  2001 Nov-Dec       Impact factor: 3.921

7.  Proteomic analysis of protein phosphorylation and ubiquitination in Alzheimer's disease.

Authors:  Stefani N Thomas; Diane Cripps; Austin J Yang
Journal:  Methods Mol Biol       Date:  2009

Review 8.  A canine model of human aging and Alzheimer's disease.

Authors:  Elizabeth Head
Journal:  Biochim Biophys Acta       Date:  2013-03-23

9.  Ovariectomy and 17beta-estradiol replacement do not alter beta-amyloid levels in sheep brain.

Authors:  A M Barron; M Cake; G Verdile; R N Martins
Journal:  Endocrinology       Date:  2009-03-12       Impact factor: 4.736

10.  Natural non-trasgenic animal models for research in Alzheimer's disease.

Authors:  Manuel Sarasa; Pedro Pesini
Journal:  Curr Alzheimer Res       Date:  2009-04       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.